[go: up one dir, main page]

Peyronie's disease: a "triple oxygenant therapy"

Arch Ital Urol Androl. 2013 Apr 19;85(1):36-40. doi: 10.4081/aiua.2013.1.36.

Abstract

Objectives: To evaluate the effects of upregulators of nitric oxide in one patient with Peyronie’s disease, after non significant improvement following intracavernosal verapamil.

Methods: A 20-years-old Caucasian male presented with penile induration in flaccid state, persistent during erection and associated with mild pain at third middle of penis. After treatment with intracavernosal verapamil for 4 months with relief of penile discomfort, followed by counseling on the use of penile extender for at least 6 hours per day, he was prescribed pentoxifylline associated with tadalafil plus levo-arginine, propionil-carnitine and Vitamin B3.

Results: After almost 2 years, the septal thickness was reduced at ultrasound evaluation after this “triple oxygenant therapy”.

Conclusion: NO-iNOS biology in Peyronie patients is the very protagonist in modulating penile fibrosis through up-regulation of NO-cGMP pathway that influences penile health by preventing and reversing fibrosis in the tunical albuginea.

Publication types

  • Case Reports

MeSH terms

  • Arginine / therapeutic use*
  • Carbolines / therapeutic use*
  • Drug Therapy, Combination
  • Free Radical Scavengers / therapeutic use*
  • Humans
  • Male
  • Penile Induration / drug therapy*
  • Pentoxifylline / therapeutic use*
  • Phosphodiesterase 5 Inhibitors / therapeutic use*
  • Tadalafil
  • Young Adult

Substances

  • Carbolines
  • Free Radical Scavengers
  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
  • Arginine
  • Pentoxifylline